Your session is about to expire
← Back to Search
Antiviral
Hepatitis C Medication for Hepatitis C Organ Transplant
Phase 4
Recruiting
Led By Lindsey Baden, MD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post-transplant
Awards & highlights
Summary
This trial uses antiviral medications to treat or prevent Hepatitis C in adults waiting for heart, lung, or kidney transplants who receive organs from Hepatitis C positive donors. The medications work by stopping the virus from multiplying in the body. These antiviral agents have been shown to be highly effective in treating Hepatitis C infection.
Eligible Conditions
- Hepatitis C
- Awaiting Organ Transplant
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months post-transplant
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post-transplant
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Graft survival
HCV status of the transplant recipient
Secondary study objectives
Treatment related adverse events
Trial Design
2Treatment groups
Experimental Treatment
Group I: HCV NAT Positive DonorExperimental Treatment1 Intervention
Intervention: 2 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily
Participants who receive allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant.
Group II: HCV NAT Negative, HCV Ab Positive DonorExperimental Treatment2 Interventions
Intervention: HCV viral load monitoring
Participants who receive allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sofosbuvir/velpatasvir
2019
Completed Phase 4
~3800
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,653 Previous Clinical Trials
11,490,887 Total Patients Enrolled
Lindsey Baden, MDPrincipal Investigator - Brigham and Women's Hospital
Brigham & Women's Hospital, Brigham and Women's Physicians Organization, Dana-Farber Cancer Institute
A Einstein College Of Medical Of Yeshiva University (Medical School)
Beth Israel Deaconess Medical Center (Residency)
7 Previous Clinical Trials
817 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: HCV NAT Positive Donor
- Group 2: HCV NAT Negative, HCV Ab Positive Donor
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger